Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
May 31, 2026
,
Atkins, M. et al.
ASCO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies.
ASCO
American Society of Clinical Oncology (ASCO)
June 1, 2022
,
O'Day, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab.
AACR
American Association for Cancer Research (AACR)
June 1, 2022
,
Shapiro, et al.
No items found.
AGEN2373 (CD137 Agonist)
Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors.
ASCO
American Society of Clinical Oncology (ASCO)
May 31, 2022
,
Tolcher, et al.
No items found.